|
1
|
Micheau O and Tschopp J: Induction of TNF
receptor I-mediated apoptosis via two sequential signaling
complexes. Cell. 114:181–190. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Graninger WB, Steiner CW, Graninger MT,
Aringer M and Smolen JS: Cytokine regulation of apoptosis and Bcl-2
expression in lymphocytes of patients with systemic lupus
erythematosus. Cell Death Differ. 7:966–972. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choy EH and Panayi GS: Cytokine pathways
and joint inflammation in rheumatoid arthritis. N Engl J Med.
344:907–916. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sands BE and Kaplan GG: The role of
TNFalpha in ulcerative colitis. J Clin Pharmacol. 47:930–941. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adegbola SO, Sahnan K, Warusavitarne J,
Hart A and Tozer P: Anti-TNF therapy in Crohn's disease. Int J Mol
Sci. 19:22442018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Celis R, Cuervo A, Ramirez J and Cañete
JD: Psoriatic synovitis: Singularity and potential clinical
implications. Front Med (Lausanne). 6:142019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Derakhshani A, Asadzadeh Z, Safarpour H,
Leone P, Shadbad MA, Heydari A, Baradaran B and Racanelli V:
Regulation of CTLA-4 and PD-L1 expression in relapsing-remitting
multiple sclerosis patients after treatment with fingolimod,
IFNbeta-1α, glatiramer acetate, and dimethyl fumarate drugs. J Pers
Med. 11:7212021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pegoretti V, Baron W, Laman JD and Eisel
ULM: Selective modulation of TNF-TNFRs signaling: Insights for
multiple sclerosis treatment. Front Immunol. 9:9252018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen L, Huang Z, Liao Y, Yang B and Zhang
J: Association between tumor necrosis factor polymorphisms and
rheumatoid arthritis as well as systemic lupus erythematosus: A
meta-analysis. Braz J Med Biol Res. 52:e79272019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mahto H, Tripathy R, Meher BR, Prusty BK,
Sharma M, Deogharia D, Saha AK, Panda AK and Das BK: TNF-α promoter
polymorphisms (G-238A and G-308A) are associated with
susceptibility to Systemic Lupus Erythematosus (SLE) and P.
falciparum malaria: A study in malaria endemic area. Sci Rep.
9:117522019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ramirez-Bello J, Cadena-Sandoval D,
Mendoza-Rincon JF, Barbosa-Cobos RE, Sánchez-Muñoz F,
Amezcua-Guerra LM, Sierra-Martínez M and Jiménez-Morales S: Tumor
necrosis factor gene polymorphisms are associated with systemic
lupus erythematosus susceptibility or lupus nephritis in Mexican
patients. Immunol Res. 66:348–354. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Idborg H, Eketjall S, Pettersson S,
Gustafsson JT, Zickert A, Kvarnström M, Oke V, Jakobsson PJ,
Gunnarsson I and Svenungsson E: TNF-α and plasma albumin as
biomarkers of disease activity in systemic lupus erythematosus.
Lupus Sci Med. 5:e0002602018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kehrl JH, Miller A and Fauci AS: Effect of
tumor necrosis factor alpha on mitogen-activated human B cells. J
Exp Med. 166:786–791. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boussiotis VA, Nadler LM, Strominger JL
and Goldfeld AE: Tumor necrosis factor alpha is an autocrine growth
factor for normal human B cells. Proc Natl Acad Sci USA.
91:7007–7011. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rieckmann P, Tuscano JM and Kehrl JH:
Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in
B-lymphocyte function. Methods. 11:128–132. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aringer M, Stummvoll GH, Steiner G, Köller
M, Steiner CW, Höfler E, Hiesberger H, Smolen JS and Graninger WB:
Serum interleukin-15 is elevated in systemic lupus erythematosus.
Rheumatology (Oxford). 40:876–881. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gabay C, Cakir N, Moral F, Roux-Lombard P,
Meyer O, Dayer JM, Vischer T, Yazici H and Guerne PA: Circulating
levels of tumor necrosis factor soluble receptors in systemic lupus
erythematosus are significantly higher than in other rheumatic
diseases and correlate with disease activity. J Rheumatol.
24:303–308. 1997.PubMed/NCBI
|
|
18
|
Studnicka-Benke A, Steiner G, Petera P and
Smolen JS: Tumour necrosis factor alpha and its soluble receptors
parallel clinical disease and autoimmune activity in systemic lupus
erythematosus. Br J Rheumatol. 35:1067–1074. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Svenungsson E, Fei GZ, Jensen-Urstad K, de
Faire U, Hamsten A and Frostegard J: TNF-alpha: A link between
hypertriglyceridaemia and inflammation in SLE patients with
cardiovascular disease. Lupus. 12:454–461. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Svenungsson E, Gunnarsson I, Fei GZ,
Lundberg IE, Klareskog L and Frostegård J: Elevated triglycerides
and low levels of high-density lipoprotein as markers of disease
activity in association with up-regulation of the tumor necrosis
factor alpha/tumor necrosis factor receptor system in systemic
lupus erythematosus. Arthritis Rheum. 48:2533–2540. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gordon C and Salmon M: Update on systemic
lupus erythematosus: Autoantibodies and apoptosis. Clin Med (Lond).
1:10–14. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang CY, Mayo MW, Korneluk RG, Goeddel DV
and Baldwin AS Jr: NF-kappaB antiapoptosis: Induction of TRAF1 and
TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science. 281:1680–1683. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Micheau O, Lens S, Gaide O, Alevizopoulos
K and Tschopp J: NF-kappaB signals induce the expression of c-FLIP.
Mol Cell Biol. 21:5299–5305. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yan X, Xiao CW, Sun M, Tsang BK and Gibb
W: Nuclear factor kappa B activation and regulation of
cyclooxygenase type-2 expression in human amnion mesenchymal cells
by interleukin-1beta. Biol Reprod. 66:1667–1671. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jacob CO and McDevitt HO: Tumour necrosis
factor-alpha in murine autoimmune ‘lupus’ nephritis. Nature.
331:356–358. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kontoyiannis D and Kollias G: Accelerated
autoimmunity and lupus nephritis in NZB mice with an engineered
heterozygous deficiency in tumor necrosis factor. Eur J Immunol.
30:2038–2047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gordon C, Ranges GE, Greenspan JS and
Wofsy D: Chronic therapy with recombinant tumor necrosis
factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol
Immunopathol. 52:421–434. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mohan AK, Edwards ET, Coté TR, Siegel JN
and Braun MM: Drug-induced systemic lupus erythematosus and
TNF-alpha blockers. Lancet. 360:6462002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Charles PJ, Smeenk RJ, Jong JD, Feldmann M
and Maini RN: Assessment of antibodies to double-stranded DNA
induced in rheumatoid arthritis patients following treatment with
infliximab, a monoclonal antibody to tumor necrosis factor alpha:
Findings in open-label and randomized placebo-controlled trials.
Arthritis Rheum. 43:2383–2390. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Carswell EA, Old LJ, Kassel RL, Green S,
Fiore N and Williamson B: An endotoxin-induced serum factor that
causes necrosis of tumors. Proc Natl Acad Sci USA. 72:3666–3670.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Spriggs DR, Deutsch S and Kufe DW: Genomic
structure, induction, and production of TNF-alpha. Immunol Ser.
56:3–34. 1992.PubMed/NCBI
|
|
32
|
Shakhov AN, Collart MA, Vassalli P,
Nedospasov SA and Jongeneel CV: Kappa B-type enhancers are involved
in lipopolysaccharide-mediated transcriptional activation of the
tumor necrosis factor alpha gene in primary macrophages. J Exp Med.
171:35–47. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Smith RA and Baglioni C: The active form
of tumor necrosis factor is a trimer. J Biol Chem. 262:6951–6954.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eck MJ and Sprang SR: The structure of
tumor necrosis factor-alpha at 2.6 A resolution. Implications for
receptor binding. J Biol Chem. 264:17595–17605. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Watts AD, Hunt NH, Wanigasekara Y,
Bloomfield G, Wallach D, Roufogalis BD and Chaudhri G: A casein
kinase I motif present in the cytoplasmic domain of members of the
tumour necrosis factor ligand family is implicated in ‘reverse
signalling’. EMBO J. 18:2119–2126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vilcek J and Lee TH: Tumor necrosis
factor. New insights into the molecular mechanisms of its multiple
actions. J Biol Chem. 266:7313–7316. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cairns CB, Panacek EA, Harken AH and
Banerjee A: Bench to bedside: Tumor necrosis factor-alpha: From
inflammation to resuscitation. Acad Emerg Med. 7:930–941. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Camussi G, Albano E, Tetta C and Bussolino
F: The molecular action of tumor necrosis factor-alpha. Eur J
Biochem. 202:3–14. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang L, Lindholm K, Konishi Y, Li R and
Shen Y: Target depletion of distinct tumor necrosis factor receptor
subtypes reveals hippocampal neuron death and survival through
different signal transduction pathways. J Neurosci. 22:3025–3032.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Beyaert R and Fiers W: Molecular
mechanisms of tumor necrosis factor-induced cytotoxicity. What we
do understand and what we do not. FEBS Lett. 340:9–16. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Darnay BG and Aggarwal BB: Signal
transduction by tumour necrosis factor and tumour necrosis factor
related ligands and their receptors. Ann Rheum Dis. 58 (Suppl
1):I2–I13. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kalliolias GD and Ivashkiv LB: TNF
biology, pathogenic mechanisms and emerging therapeutic strategies.
Nat Rev Rheumatol. 12:49–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fiers W: Tumor necrosis factor.
Characterization at the molecular, cellular and in vivo level. FEBS
Lett. 285:199–212. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jang DI, Lee AH, Shin HY, Song HR, Park
JH, Kang TB, Lee SR and Yang SH: The role of tumor necrosis factor
alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in
therapeutics. Int J Mol Sci. 22:27192021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fuchs P, Strehl S, Dworzak M, Himmler A
and Ambros PF: Structure of the human TNF receptor 1 (p60) gene
(TNFR1) and localization to chromosome 12p13 [corrected]. Genomics.
13:219–224. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang XY, Kafka M, Dvilansky A and Nathan
I: The roles of protein phosphorylation/dephosphorylation in tumor
necrosis factor antitumor effects. J Interferon Cytokine Res.
16:1021–1025. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kemper O and Wallach D: Cloning and
partial characterization of the promoter for the human p55 tumor
necrosis factor (TNF) receptor. Gene. 134:209–216. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Desplat-Jego S, Burkly L and Putterman C:
Targeting TNF and its family members in autoimmune/inflammatory
disease. Mediators Inflamm. 2014:6287482014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bodmer JL, Schneider P and Tschopp J: The
molecular architecture of the TNF superfamily. Trends Biochem Sci.
27:19–26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Locksley RM, Killeen N and Lenardo MJ: The
TNF and TNF receptor superfamilies: Integrating mammalian biology.
Cell. 104:487–501. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Grell M: Tumor necrosis factor (TNF)
receptors in cellular signaling of soluble and membrane-expressed
TNF. J Inflamm. 47:8–17. 1995.PubMed/NCBI
|
|
52
|
Hsu H, Xiong J and Goeddel DV: The TNF
receptor 1-associated protein TRADD signals cell death and NF-kappa
B activation. Cell. 81:495–504. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sedger LM and McDermott MF: TNF and
TNF-receptors: From mediators of cell death and inflammation to
therapeutic giants-past, present and future. Cytokine Growth Factor
Rev. 25:453–472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Faustman D and Davis M: TNF receptor 2
pathway: Drug target for autoimmune diseases. Nat Rev Drug Discov.
9:482–493. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Grell M, Wajant H, Zimmermann G and
Scheurich P: The type 1 receptor (CD120a) is the high-affinity
receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA.
95:570–575. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wajant H, Pfizenmaier K and Scheurich P:
Tumor necrosis factor signaling. Cell Death Differ. 10:45–65. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tartaglia LA, Ayres TM, Wong GH and
Goeddel DV: A novel domain within the 55 kd TNF receptor signals
cell death. Cell. 74:845–853. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Bradley JR: TNF-mediated inflammatory
disease. J Pathol. 214:149–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fischer R, Maier O, Naumer M,
Krippner-Heidenreich A, Scheurich P and Pfizenmaier K:
Ligand-induced internalization of TNF receptor 2 mediated by a
di-leucin motif is dispensable for activation of the NFκB pathway.
Cell Signal. 23:161–170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Naude PJ, den Boer JA, Luiten PG and Eisel
UL: Tumor necrosis factor receptor cross-talk. FEBS J. 278:888–898.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Marchetti L, Klein M, Schlett K,
Pfizenmaier K and Eisel ULM: Tumor necrosis factor (TNF)-mediated
neuroprotection against glutamate-induced excitotoxicity is
enhanced by N-methyl-D-aspartate receptor activation. Essential
role of a TNF receptor 2-mediated phosphatidylinositol
3-kinase-dependent NF-kappa B pathway. J Biol Chem.
279:32869–32881. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Goto N, Tsurumi H, Takemura M, Hara T,
Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu M, Takahashi T,
et al: Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2)
level determines clinical outcome in patients with aggressive
non-Hodgkin's lymphoma. Eur J Haematol. 77:217–225. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kanayama A, Seth RB, Sun L, Ea CK, Hong M,
Shaito A, Chiu YH, Deng L and Chen ZJ: TAB2 and TAB3 activate the
NF-kappaB pathway through binding to polyubiquitin chains. Mol
Cell. 15:535–548. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Haas TL, Emmerich CH, Gerlach B, Schmukle
AC, Cordier SM, Rieser E, Feltham R, Vince J, Warnken U, Wenger T,
et al: Recruitment of the linear ubiquitin chain assembly complex
stabilizes the TNF-R1 signaling complex and is required for
TNF-mediated gene induction. Mol Cell. 36:831–844. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Tokunaga F, Sakata S, Saeki Y, Satomi Y,
Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S, et
al: Involvement of linear polyubiquitylation of NEMO in NF-kappaB
activation. Nat Cell Biol. 11:123–132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Sabio G and Davis RJ: TNF and MAP kinase
signalling pathways. Semin Immunol. 26:237–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zeke A, Misheva M, Reményi A and
Bogoyevitch MA: JNK signaling: Regulation and functions based on
complex protein-protein partnerships. Microbiol Mol Biol Rev.
80:793–835. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Itoh N and Nagata S: A novel protein
domain required for apoptosis. Mutational analysis of human fas
antigen. J Biol Chem. 268:10932–10937. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Vercammen D, Beyaert R, Denecker G,
Goossens V, Loo GV, Declercq W, Grooten J, Fiers W and Vandenabeele
P: Inhibition of caspases increases the sensitivity of L929 cells
to necrosis mediated by tumor necrosis factor. J Exp Med.
187:1477–1485. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Shalini S, Dorstyn L, Dawar S and Kumar S:
Old, new and emerging functions of caspases. Cell Death Differ.
22:526–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Samson AL, Zhang Y, Geoghegan ND, Gavin
XJ, Davies KA, Mlodzianoski MJ, Whitehead LW, Frank D, Garnish SE,
Fitzgibbon C, et al: MLKL trafficking and accumulation at the
plasma membrane control the kinetics and threshold for necroptosis.
Nat Commun. 11:31512020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Rothe M, Wong SC, Henzel WJ and Goeddel
DV: A novel family of putative signal transducers associated with
the cytoplasmic domain of the 75 kDa tumor necrosis factor
receptor. Cell. 78:681–692. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Borghi A, Haegman M, Fischer R, Carpentier
I, Bertrand MJM, Libert C, Afonina IS and Beyaert R: The E3
ubiquitin ligases HOIP and cIAP1 are recruited to the TNFR2
signaling complex and mediate TNFR2-induced canonical NF-kappaB
signaling. Biochem Pharmacol. 153:292–298. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Rauert H, Wicovsky A, Muller N, Siegmund
D, Spindler V, Waschke J, Kneitz C and Wajant H: Membrane tumor
necrosis factor (TNF) induces p100 processing via TNF receptor-2
(TNFR2). J Biol Chem. 285:7394–7404. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Sun SC: The non-canonical NF-κB pathway in
immunity and inflammation. Nat Rev Immunol. 17:545–558. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Devin A, Cook A, Lin Y, Rodriguez Y,
Kelliher M and Liu Z: The distinct roles of TRAF2 and RIP in IKK
activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP
mediates IKK activation. Immunity. 12:419–429. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Fotin-Mleczek M, Henkler F, Samel D,
Reichwein M, Hausser A, Parmryd I, Scheurich P, Schmid JA and
Wajant H: Apoptotic crosstalk of TNF receptors: TNF-R2-induces
depletion of TRAF2 and IAP proteins and accelerates
TNF-R1-dependent activation of caspase-8. J Cell Sci.
115:2757–2770. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Li X, Yang Y and Ashwell JD: TNF-RII and
c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature.
416:345–347. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tada K, Okazaki T, Sakon S, Kobarai T,
Kurosawa K, Yamaoka S, Hashimoto H, Mak TW, Yagita H, Okumura K, et
al: Critical roles of TRAF2 and TRAF5 in tumor necrosis
factor-induced NF-kappa B activation and protection from cell
death. J Biol Chem. 276:36530–36534. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Vince JE, Pantaki D, Feltham R, Mace PD,
Cordier SM, Schmukle AC, Davidson AJ, Callus BA, Wong WWL, Gentle
IE, et al: TRAF2 must bind to cellular inhibitors of apoptosis for
tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and
to prevent tnf-induced apoptosis. J Biol Chem. 284:35906–35915.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Liu ZG, Hsu H, Goeddel DV and Karin M:
Dissection of TNF receptor 1 effector functions: JNK activation is
not linked to apoptosis while NF-kappaB activation prevents cell
death. Cell. 87:565–576. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ridgley LA, Anderson AE and Pratt AG: What
are the dominant cytokines in early rheumatoid arthritis? Curr Opin
Rheumatol. 30:207–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kobayashi M, Squires GR, Mousa A, Tanzer
M, Zukor DJ, Antoniou J, Feige U and Poole AR: Role of
interleukin-1 and tumor necrosis factor alpha in matrix degradation
of human osteoarthritic cartilage. Arthritis Rheum. 52:128–135.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Mirza F, Lorenzo J, Drissi H, Lee FY and
Soung DY: Dried plum alleviates symptoms of inflammatory arthritis
in TNF transgenic mice. J Nutr Biochem. 52:54–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Chen W, Li Z, Wang Z, Gao H, Ding J and He
Z: Intraarticular injection of infliximab-loaded thermosensitive
hydrogel alleviates pain and protects cartilage in rheumatoid
arthritis. J Pain Res. 13:3315–3329. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Rioja I, Bush KA, Buckton JB, Dickson MC
and Life PF: Joint cytokine quantification in two rodent arthritis
models: Kinetics of expression, correlation of mRNA and protein
levels and response to prednisolone treatment. Clin Exp Immunol.
137:65–73. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Williams RO, Marinova-Mutafchieva L,
Feldmann M and Maini RN: Evaluation of TNF-alpha and IL-1 blockade
in collagen-induced arthritis and comparison with combined
anti-TNF-alpha/anti-CD4 therapy. J Immunol. 165:7240–7245. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yu D, Ye X, Che R, Wu Q, Qi J, Song L, Guo
X, Zhang S, Wu H, Ren G and Li D: FGF21 exerts comparable
pharmacological efficacy with Adalimumab in ameliorating
collagen-induced rheumatoid arthritis by regulating systematic
inflammatory response. Biomed Pharmacother. 89:751–760. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wu AJ, Hua H, Munson SH and McDevitt HO:
Tumor necrosis factor-alpha regulation of
CD4+CD25+ T cell levels in NOD mice. Proc
Natl Acad Sci USA. 99:12287–12292. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ehrenstein MR, Evans JG, Singh A, Moore S,
Warnes G, Isenberg DA and Mauri C: Compromised function of
regulatory T cells in rheumatoid arthritis and reversal by
anti-TNFalpha therapy. J Exp Med. 200:277–285. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Louis E: The immuno-inflammatory reaction
in Crohn's disease and ulcerative colitis: Characterisation,
genetics and clinical application. Focus on TNF alpha. Acta
Gastroenterol Belg. 64:1–5. 2001.PubMed/NCBI
|
|
92
|
Gottlieb AB, Chamian F, Masud S, Cardinale
I, Abello MV, Lowes MA, Chen F, Magliocco M and Krueger JG: TNF
inhibition rapidly down-regulates multiple proinflammatory pathways
in psoriasis plaques. J Immunol. 175:2721–2729. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Catalina MD, Owen KA, Labonte AC, Grammer
AC and Lipsky PE: The pathogenesis of systemic lupus erythematosus:
Harnessing big data to understand the molecular basis of lupus. J
Autoimmun. 110:1023592020. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kwon YC, Chun S, Kim K and Mak A: Update
on the genetics of systemic lupus erythematosus: Genome-wide
association studies and beyond. Cells. 8:11802019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Marion TN and Postlethwaite AE: Chance,
genetics, and the heterogeneity of disease and pathogenesis in
systemic lupus erythematosus. Semin Immunopathol. 36:495–517. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Hedrich CM: Epigenetics in SLE. Curr
Rheumatol Rep. 19:582017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Pan L, Lu MP, Wang JH, Xu M and Yang SR:
Immunological pathogenesis and treatment of systemic lupus
erythematosus. World J Pediatr. 16:19–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Maningding E, Dall'Era M, Trupin L, Murphy
LB and Yazdany J: Racial and ethnic differences in the prevalence
and time to onset of manifestations of systemic lupus
erythematosus: The California lupus surveillance project. Arthritis
Care Res (Hoboken). 72:622–629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Christou EAA, Banos A, Kosmara D, Bertsias
GK and Boumpas DT: Sexual dimorphism in SLE: Above and beyond sex
hormones. Lupus. 28:3–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Barbhaiya M and Costenbader KH:
Environmental exposures and the development of systemic lupus
erythematosus. Curr Opin Rheumatol. 28:497–505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Constantin MM, Nita IE, Olteanu R,
Constantin T, Bucur S, Matei C and Raducan A: Significance and
impact of dietary factors on systemic lupus erythematosus
pathogenesis. Exp Ther Med. 17:1085–1090. 2019.PubMed/NCBI
|
|
102
|
Luo S, Long H and Lu Q: Recent advances in
understanding pathogenesis and therapeutic strategies of systemic
lupus erythematosus. Int Immunopharmacol. 89:1070282020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Parks CG, de Souza Espindola Santos A,
Barbhaiya M and Costenbader KH: Understanding the role of
environmental factors in the development of systemic lupus
erythematosus. Best Pract Res Clin Rheumatol. 31:306–320. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Habib HM, Taher TE, Isenberg DA and Mageed
RA: Enhanced propensity of T lymphocytes in patients with systemic
lupus erythematosus to apoptosis in the presence of tumour necrosis
factor alpha. Scand J Rheumatol. 38:112–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gómez D, Correa PA, Gómez LM, Cadena J,
Molina JF and Anaya JM: Th1/Th2 cytokines in patients with systemic
lupus erythematosus: Is tumor necrosis factor alpha protective?
Semin Arthritis Rheum. 33:404–413. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhu L, Yang X, Chen W, Li X, Ji Y, Mao H,
Nie J and Yu X: Decreased expressions of the TNF-alpha signaling
adapters in peripheral blood mononuclear cells (PBMCs) are
correlated with disease activity in patients with systemic lupus
erythematosus. Clin Rheumatol. 26:1481–1489. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
McCarthy EM, Smith S, Lee RZ, Cunnane G,
Doran MF, Donnelly S, Howard D, O'Connell P, Kearns G, Gabhann JN
and Jefferies CA: The association of cytokines with disease
activity and damage scores in systemic lupus erythematosus
patients. Rheumatology (Oxford). 53:1586–1594. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Prete M, Leone P, Frassanito MA, Desantis
V, Marasco C, Cicco S, Dammacco F, Vacca A and Racanelli V:
Belimumab restores Treg/Th17 balance in patients with refractory
systemic lupus erythematosus. Lupus. 27:1926–1935. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Su DL, Lu ZM, Shen MN, Li X and Sun LY:
Roles of pro- and anti-inflammatory cytokines in the pathogenesis
of SLE. J Biomed Biotechnol. 2012:3471412012. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Tahernia L, Alimadadi H, Tahghighi F,
Amini Z and Ziaee V: Frequency and type of hepatic and
gastrointestinal involvement in juvenile systemic lupus
erythematosus. Autoimmune Dis. 2017:80972732017.PubMed/NCBI
|
|
111
|
Yap DY and Lai KN: The role of cytokines
in the pathogenesis of systemic lupus erythematosus-from bench to
bedside. Nephrology (Carlton). 18:243–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Takemura T, Yoshioka K, Murakami K, Akano
N, Okada M, Aya N and Maki S: Cellular localization of inflammatory
cytokines in human glomerulonephritis. Virchows Arch. 424:459–464.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Malide D, Russo P and Bendayan M: Presence
of tumor necrosis factor alpha and interleukin-6 in renal mesangial
cells of lupus nephritis patients. Hum Pathol. 26:558–564. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Neale TJ, Ruger BM, Macaulay H, Dunbar PR,
Hasan Q, Bourke A, Murray-McIntosh RP and Kitching AR: Tumor
necrosis factor-alpha is expressed by glomerular visceral
epithelial cells in human membranous nephropathy. Am J Pathol.
146:1444–1454. 1995.PubMed/NCBI
|
|
115
|
Herrera-Esparza R, Barbosa-Cisneros O,
Villalobos-Hurtado R and Avalos-Díaz E: Renal expression of IL-6
and TNFalpha genes in lupus nephritis. Lupus. 7:154–158. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Aringer M and Smolen JS: The role of tumor
necrosis factor-alpha in systemic lupus erythematosus. Arthritis
Res Ther. 10:2022008. View
Article : Google Scholar : PubMed/NCBI
|
|
117
|
D'Alfonso S, Colombo G, Bella SD, Scorza R
and Momigliano-Richiardi P: Association between polymorphisms in
the TNF region and systemic lupus erythematosus in the Italian
population. Tissue Antigens. 47:551–555. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Dourmishev L, Kamenarska Z, Hristova M,
Dodova R, Kaneva R and Mitev V: Association of TNF-α polymorphisms
with adult dermatomyositis and systemic lupus erythematosus in
Bulgarian patients. Int J Dermatol. 51:1467–1473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Lee YH, Harley JB and Nath SK:
Meta-analysis of TNF-alpha promoter-308 A/G polymorphism and SLE
susceptibility. Eur J Hum Genet. 14:364–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Lin YJ, Chen RH, Wan L, Sheu JC, Huang CM,
Lin CW, Chen SY, Lai CH, Lan YC, Hsueh KC, et al: Association of
TNF-alpha gene polymorphisms with systemic lupus erythematosus in
Taiwanese patients. Lupus. 18:974–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zúñiga J, Vargas-Alarcón G,
Hernández-Pacheco G, Portal-Celhay C, Yamamoto-Furusho JK and
Granados J: Tumor necrosis factor-alpha promoter polymorphisms in
Mexican patients with systemic lupus erythematosus (SLE). Genes
Immun. 2:363–366. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Davas EM, Tsirogianni A, Kappou I,
Karamitsos D, Economidou I and Dantis PC: Serum IL-6, TNFalpha, p55
srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity
in systemic lupus erythematosus. Clin Rheumatol. 18:17–22. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Adrianto I, Wen F, Templeton A, Wiley G,
King JB, Lessard CJ, Bates JS, Hu Y, Kelly JA, Kaufman KM, et al:
Association of a functional variant downstream of TNFAIP3 with
systemic lupus erythematosus. Nat Genet. 43:253–258. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Bates JS, Lessard CJ, Leon JM, Nguyen T,
Battiest LJ, Rodgers J, Kaufman KM, James JA, Gilkeson GS, Kelly
JA, et al: Meta-analysis and imputation identifies a 109 kb risk
haplotype spanning TNFAIP3 associated with lupus nephritis and
hematologic manifestations. Genes Immun. 10:470–477. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Goulielmos GN, Zervou MI, Vazgiourakis VM,
Ghodke-Puranik Y, Garyfallos A and Niewold TB: The genetics and
molecular pathogenesis of systemic lupus erythematosus (SLE) in
populations of different ancestry. Gene. 668:59–72. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Manku H, Langefeld CD, Guerra SG, Malik
TH, Alarcon-Riquelme M, Anaya JM, Bae SC, Boackle SA, Brown EE,
Criswell LA, et al: Trans-ancestral studies fine map the
SLE-susceptibility locus TNFSF4. PLoS Genet. 9:e10035542013.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Komata T, Tsuchiya N, Matsushita M,
Hagiwara K and Tokunaga K: Association of tumor necrosis factor
receptor 2 (TNFR2) polymorphism with susceptibility to systemic
lupus erythematosus. Tissue Antigens. 53:527–533. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Aderka D, Wysenbeek A, Engelmann H, Cope
AP, Brennan F, Molad Y, Hornik V, Levo Y, Maini RN and Feldmann M:
Correlation between serum levels of soluble tumor necrosis factor
receptor and disease activity in systemic lupus erythematosus.
Arthritis Rheum. 36:1111–1120. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Munroe ME, Vista ES, Guthridge JM,
Thompson LF, Merrill JT and James JA: Proinflammatory adaptive
cytokine and shed tumor necrosis factor receptor levels are
elevated preceding systemic lupus erythematosus disease flare.
Arthritis Rheumatol. 66:1888–1899. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Horiuchi T, Mitoma H, Harashima S,
Tsukamoto H and Shimoda T: Transmembrane TNF-alpha: Structure,
function and interaction with anti-TNF agents. Rheumatology
(Oxford). 49:1215–1228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Patel M, Oni L, Midgley A, Smith E, Tullus
K, Marks SD, Jones CA, Pilkington C and Beresford MW: Increased
concentration of plasma TNFR1 and TNFR2 in paediatric lupus
nephritis. Lupus. 25:1040–1044. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Ida H, Kawasaki E, Miyashita T, Tanaka F,
Kamachi M, Izumi Y, Huang M, Tamai M, Origuchi T, Kawakami A, et
al: A novel mutation (T61I) in the gene encoding tumour necrosis
factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient
with tumour necrosis factor receptor-associated periodic syndrome
(TRAPS) associated with systemic lupus erythematosus. Rheumatology
(Oxford). 43:1292–1299. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Al-Ansari AS, Ollier WE, Villarreal J,
Ordi J, The LS and Hajeer AH: Tumor necrosis factor receptor II
(TNFRII) exon 6 polymorphism in systemic lupus erythematosus.
Tissue Antigens. 55:97–99. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Chadha S, Miller K, Farwell L, Sacks S,
Daly MJ, Rioux JD and Vyse TJ: Haplotype analysis of tumour
necrosis factor receptor genes in 1p36: No evidence for association
with systemic lupus erythematosus. Eur J Hum Genet. 14:69–78. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Sullivan KE, Piliero LM, Goldman D and
Petri MA: A TNFR2 3′ flanking region polymorphism in systemic lupus
erythematosus. Genes Immun. 1:225–227. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Fairhurst AM, Wandstrat AE and Wakeland
EK: Systemic lupus erythematosus: Multiple immunological phenotypes
in a complex genetic disease. Adv Immunol. 92:1–69. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Li W, Titov AA and Morel L: An update on
lupus animal models. Curr Opin Rheumatol. 29:434–441. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Aringer M and Smolen JS: Therapeutic
blockade of TNF in patients with SLE-promising or crazy? Autoimmun
Rev. 11:321–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Helyer BJ and Howie JB: Renal disease
associated with positive lupus erythematosus tests in a cross-bred
strain of mice. Nature. 197:1971963. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Brennan DC, Yui MA, Wuthrich RP and Kelley
VE: Tumor necrosis factor and IL-1 in New Zealand black/white mice.
Enhanced gene expression and acceleration of renal injury. J
Immunol. 143:3470–3475. 1989.PubMed/NCBI
|
|
141
|
Boswell JM, Yui MA, Burt DW and Kelley VE:
Increased tumor necrosis factor and IL-1 beta gene expression in
the kidneys of mice with lupus nephritis. J Immunol. 141:3050–3054.
1988.PubMed/NCBI
|
|
142
|
Yokoyama H, Kreft B and Kelley VR:
Biphasic increase in circulating and renal TNF-alpha in MRL-lpr
mice with differing regulatory mechanisms. Kidney Int. 47:122–130.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Tsai CY, Wu TH, Huang SF, Sun KH, Hsieh
SC, Han SH, Yu HS and Yu CL: Abnormal splenic and thymic IL-4 and
TNF-alpha expression in MRL-lpr/lpr mice. Scand J Immunol.
41:157–163. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Deguchi Y and Kishimoto S: Tumour necrosis
factor/cachectin plays a key role in autoimmune pulmonary
inflammation in lupus-prone mice. Clin Exp Immunol. 85:392–395.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Su X, Zhou T, Yang P, Edwards CK III and
Mountz JD: Reduction of arthritis and pneumonitis in motheaten mice
by soluble tumor necrosis factor receptor. Arthritis Rheum.
41:139–149. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Bethunaickan R, Sahu R, Liu Z, Tang YT,
Huang W, Edegbe O, Tao H, Ramanujam M, Madaio MP and Davidson A:
Anti-tumor necrosis factor alpha treatment of interferon-α-induced
murine lupus nephritis reduces the renal macrophage response but
does not alter glomerular immune complex formation. Arthritis
Rheum. 64:3399–3408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Monaco C, Nanchahal J, Taylor P and
Feldmann M: Anti-TNF therapy: Past, present and future. Int
Immunol. 27:55–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Williams EL, Gadola S and Edwards CJ:
Anti-TNF-induced lupus. Rheumatology (Oxford). 48:716–720. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Aghdashi MA, Khadir M and Dinparasti-Saleh
R: Antinuclear antibodies and lupus-like manifestations in
rheumatoid arthritis and ankylosing spondylitis patients at 4
months' follow-up after treatment with infliximab and etanercept.
Curr Rheumatol Rev. 16:61–66. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Gonnet-Gracia C, Barnetche T, Richez C,
Blanco P, Dehais J and Schaeverbeke T: Anti-nuclear antibodies,
anti-DNA and C4 complement evolution in rheumatoid arthritis and
ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp
Rheumatol. 26:401–407. 2008.PubMed/NCBI
|
|
151
|
Ramos-Casals M, Brito-Zeron P, Munoz S,
Soria N, Galiana D, Bertolaccini L, Cuadrado MJ and Khamashta MA:
Autoimmune diseases induced by TNF-targeted therapies: Analysis of
233 cases. Medicine (Baltimore). 86:242–251. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Santos CS, Castro CA, Morales CM and
Álvarez ED: Anti-TNF-α-induced lupus syndrome: Two case reports and
review of current literature. Z Rheumatol. 80:481–486. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Stokes MB, Foster K, Markowitz GS,
Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D and D'Agati VD:
Development of glomerulonephritis during anti-TNF-alpha therapy for
rheumatoid arthritis. Nephrol Dial Transplant. 20:1400–1406. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Mor A, Bingham CO III, Barisoni L, Lydon E
and Belmont HM: Proliferative lupus nephritis and leukocytoclastic
vasculitis during treatment with etanercept. J Rheumatol.
32:740–743. 2005.PubMed/NCBI
|
|
155
|
Aringer M, Graninger WB, Steiner G and
Smolen JS: Safety and efficacy of tumor necrosis factor alpha
blockade in systemic lupus erythematosus: An open-label study.
Arthritis Rheum. 50:3161–3169. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Aringer M, Steiner G, Graninger WB, Höfler
E, Steiner CW and Smolen JS: Effects of short-term infliximab
therapy on autoantibodies in systemic lupus erythematosus.
Arthritis Rheum. 56:274–279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Aringer M, Houssiau F, Gordon C, Graninger
WB, Voll RE, Rath E, Steiner G and Smolen JS: Adverse events and
efficacy of TNF-alpha blockade with infliximab in patients with
systemic lupus erythematosus: long-term follow-up of 13 patients.
Rheumatology (Oxford). 48:1451–1454. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Matsumura R, Umemiya K, Sugiyama T,
Sueishi M, Umibe T, Ichikawa K and Yoshimura M; Study Group on
Nephrology at the National Hospital Organization of Japan, :
Anti-tumor necrosis factor therapy in patients with
difficult-to-treat lupus nephritis: A prospective series of nine
patients. Clin Exp Rheumatol. 27:416–421. 2009.PubMed/NCBI
|
|
159
|
Hayat SJ and Uppal SS: Therapeutic
efficacy and safety profile of infliximab in active systemic lupus
erythematosus. Mod Rheumatol. 17:174–177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Uppal SS, Hayat SJ and Raghupathy R:
Efficacy and safety of infliximab in active SLE: A pilot study.
Lupus. 18:690–697. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Moreland LW, Baumgartner SW, Schiff MH,
Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S,
Koopman WJ, Mohler K, et al: Treatment of rheumatoid arthritis with
a recombinant human tumor necrosis factor receptor (p75)-Fc fusion
protein. N Engl J Med. 337:141–147. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Anderson PJ: Tumor necrosis factor
inhibitors: Clinical implications of their different immunogenicity
profiles. Semin Arthritis Rheum. 34 5 Suppl 1:S19–S22. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Cortes-Hernandez J, Egri N,
Vilardell-Tarres M and Ordi-Ros J: Etanercept in refractory lupus
arthritis: An observational study. Semin Arthritis Rheum.
44:672–679. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Norman R, Greenberg RG and Jackson JM:
Case reports of etanercept in inflammatory dermatoses. J Am Acad
Dermatol. 54 3 Suppl 2:S139–S142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Yang BB, Xiao H, Li XJ and Zheng M: Safety
and efficacy of etanercept-methotrexate combination therapy in
patients with rhupus: An observational study of non-glucocorticoid
treatment for rheumatic diseases. Discov Med. 25:14–20.
2018.PubMed/NCBI
|
|
166
|
Danion F, Sparsa L, Arnaud L, Alsaleh G,
Lefebvre F, Gies V, Martin T, Lukas C, Durckel J, Ardizzone M, et
al: Long-term efficacy and safety of antitumour necrosis factor
alpha treatment in rhupus: An open-label study of 15 patients. RMD
Open. 3:e0005552017. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Micheloud D, Nuno L, Rodriguez-Mahou M,
Sánchez-Ramón S, Ortega MC, Aguarón A, Junco E, Carbone J,
Fernández-Cruzl E, Carreño L and López-Longo FJ: Efficacy and
safety of Etanercept, high-dose intravenous gammaglobulin and
plasmapheresis combined therapy for lupus diffuse proliferative
nephritis complicating pregnancy. Lupus. 15:881–885. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Mustafa G, Mahrosh HS, Salman M, Sharif S,
Jabeen R, Majeed T and Tahir H: Identification of peptides as novel
inhibitors to target IFN-γ, IL-3, and TNF-α in systemic lupus
erythematosus. Biomed Res Int. 2021:11240552021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Bongartz T, Sutton AJ, Sweeting MJ, Buchan
I, Matteson EL and Montori V: Anti-TNF antibody therapy in
rheumatoid arthritis and the risk of serious infections and
malignancies: Systematic review and meta-analysis of rare harmful
effects in randomized controlled trials. JAMA. 295:2275–2285. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Tack CJ, Kleijwegt FS, Van Riel PL and
Roep BO: Development of type 1 diabetes in a patient treated with
anti-TNF-alpha therapy for active rheumatoid arthritis.
Diabetologia. 52:1442–1444. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Bloom BJ: Development of diabetes mellitus
during etanercept therapy in a child with systemic-onset juvenile
rheumatoid arthritis. Arthritis Rheum. 43:2606–2608. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Kollias G and Kontoyiannis D: Role of
TNF/TNFR in autoimmunity: Specific TNF receptor blockade may be
advantageous to anti-TNF treatments. Cytokine Growth Factor Rev.
13:315–321. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Zhang N, Wang Z and Zhao Y: Selective
inhibition of Tumor necrosis factor receptor-1 (TNFR1) for the
treatment of autoimmune diseases. Cytokine Growth Factor Rev.
55:80–85. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Van Hauwermeiren F, Armaka M, Karagianni
N, Kranidioti K, Vandenbroucke RE, Loges S, Roy MV, Staelens J,
Puimège L, Palagani A, et al: Safe TNF-based antitumor therapy
following p55TNFR reduction in intestinal epithelium. J Clin
Invest. 123:2590–2603. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Puimege L, Libert C and Van Hauwermeiren
F: Regulation and dysregulation of tumor necrosis factor
receptor-1. Cytokine Growth Factor Rev. 25:285–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Vinay DS and Kwon BS: The tumour necrosis
factor/TNF receptor superfamily: Therapeutic targets in autoimmune
diseases. Clin Exp Immunol. 164:145–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N,
Calixto S, Mackay M, Aranow C, Putterman C and Mohan C: Elevated
urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC
chemokine ligand 16 in multiple murine lupus strains and human
lupus nephritis. J Immunol. 179:7166–7175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Deng GM, Liu L and Tsokos GC: Targeted
tumor necrosis factor receptor I preligand assembly domain improves
skin lesions in MRL/lpr mice. Arthritis Rheum. 62:2424–2431. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Jacob N, Yang H, Pricop L, Liu Y, Gao X,
Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, et al: Accelerated
pathological and clinical nephritis in systemic lupus
erythematosus-prone New Zealand mixed 2328 mice doubly deficient in
TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J
Immunol. 182:2532–2541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Zhou T, Edwards CK III, Yang P, Wang Z,
Bluethmann H and Mountz JD: Greatly accelerated lymphadenopathy and
autoimmune disease in lpr mice lacking tumor necrosis factor
receptor I. J Immunol. 156:2661–2665. 1996.PubMed/NCBI
|
